Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Hematology Analyzers Offer Channel for Immature Platelet Fraction

By LabMedica International staff writers
Posted on 18 Jul 2012
AACC 2012: A hematology analyzer includes a fluorescent platelet channel for Immature Platelet Fraction (IPF), which will aid in the differential diagnosis of thrombocytopenia. The scalable, series-wide compact design delivers a smaller footprint that improves workflow and transforms productivity.

The analyzers are among products from Sysmex's hematology, urinalysis, cell image analysis, and middleware portfolio that are on show at the annual AACC/AACLS conference Expo being held July 15-19, 2012, in Los Angeles, (CA, USA).

The Sysmex (Mundelein, IL, USA) XN-Series Hematology Analyzers enable laboratories of any size to implement advanced clinical parameters. The scalable, series-wide compact design delivers a smaller footprint that optimizes workflow and transforms productivity. The instruments are built on the concept of Silent Design, a fusion of product design and technology.

Expo in-booth educational presentations will feature topics about hematology technology, diabetes management, and advanced clinical parameters, among others. Sysmex manufactures clinical laboratory solutions, including clinical diagnostics, automation, and information systems, and services hospitals and healthcare networks, reference laboratories, and physicians' offices worldwide.

The Sysmex XN-Series Hematology Analyzer has been designed to enable clinical laboratories to withstand future medical technologist shortages; and the ability to keep up with workload demands and testing complexity that may accompany an aging population. "The human-centered approach of Silent Design, upon which the Sysmex XN-Series hematology analyzers are built, provides a simplified system of operation and interface based on careful study of laboratory processes, the relationship between the operator and the instrument, and how people work," said Ralph Taylor, executive vice president, marketing, business development, and medical affairs, Sysmex America, Inc.

Related Links:

Sysmex America




Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Ultrasonic Cleaner
UC 300 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.